For example, when COPD patients were infused with a human anti-IL-1β monoclonal antibody called canakinumab for 45 weeks, their forced expiratory volume in 1 s and forced vital capacity did not improve when compared to a placebo group. Here, IL1B is linked to chronic obstructive pulmonary disease.